CN112755049A - Laxative formula for improving dog cestodiasis excrement detection sensitivity and preparation method thereof - Google Patents
Laxative formula for improving dog cestodiasis excrement detection sensitivity and preparation method thereof Download PDFInfo
- Publication number
- CN112755049A CN112755049A CN202110161432.0A CN202110161432A CN112755049A CN 112755049 A CN112755049 A CN 112755049A CN 202110161432 A CN202110161432 A CN 202110161432A CN 112755049 A CN112755049 A CN 112755049A
- Authority
- CN
- China
- Prior art keywords
- improving
- cestodiasis
- sensitivity
- agent
- quick
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 57
- 230000035945 sensitivity Effects 0.000 title claims abstract description 47
- 239000008141 laxative Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000002475 laxative effect Effects 0.000 title description 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 60
- 210000003608 fece Anatomy 0.000 claims abstract description 37
- 230000001769 paralizing effect Effects 0.000 claims abstract description 31
- 230000001543 purgative effect Effects 0.000 claims abstract description 29
- 241000244155 Taenia Species 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 12
- 239000011230 binding agent Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000005303 weighing Methods 0.000 claims abstract description 5
- 241000282472 Canis lupus familiaris Species 0.000 claims description 32
- 239000003826 tablet Substances 0.000 claims description 26
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 20
- 239000002775 capsule Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- 239000000853 adhesive Substances 0.000 claims description 16
- 230000001070 adhesive effect Effects 0.000 claims description 16
- 241000282465 Canis Species 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 10
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 230000002550 fecal effect Effects 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 235000019737 Animal fat Nutrition 0.000 claims description 7
- 241000287828 Gallus gallus Species 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 229940041514 candida albicans extract Drugs 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 7
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 7
- 238000003825 pressing Methods 0.000 claims description 7
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 7
- 239000012138 yeast extract Substances 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- RNIWSOXRCLEXPV-UHFFFAOYSA-N 2,2-dichlorotetradecanal Chemical compound CCCCCCCCCCCCC(Cl)(Cl)C=O RNIWSOXRCLEXPV-UHFFFAOYSA-N 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 239000007891 compressed tablet Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- QUSPUZQKMRMVFL-UHFFFAOYSA-N 2-(benzenesulfonamido)-4-methylsulfanylbutanoic acid Chemical compound CSCCC(C(O)=O)NS(=O)(=O)C1=CC=CC=C1 QUSPUZQKMRMVFL-UHFFFAOYSA-N 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 241000242722 Cestoda Species 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 10
- 230000013872 defecation Effects 0.000 abstract description 9
- 206010033799 Paralysis Diseases 0.000 abstract description 3
- 241000244160 Echinococcus Species 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 208000004441 taeniasis Diseases 0.000 description 6
- 206010014096 Echinococciasis Diseases 0.000 description 5
- 208000009366 Echinococcosis Diseases 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 241001466804 Carnivora Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000019993 champagne Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/26—Compounds containing phosphorus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A purgative formula for improving the detection sensitivity of dog cestodiasis excrement comprises the following components by weight per Kg of a dog: 0.002g to 0.008g of a taenia paralytic agent; 3g to 6g of an quick-release agent; 3g to 6g of a binder; and 9.2g to 20.4g of phagostimulant. A preparation method of cathartic for improving the detection sensitivity of cestodiasis faeces comprises weighing the above components; mixing taenia paralytic agent and quick-release agent; the phagostimulant is made into a shell. By using the medicament provided by the invention, the average defecation time of the dog can be reduced by 2.75 times, and the sample obtaining efficiency is obviously improved. The agent provided by the invention can improve the detection rate of dog dung and dog dung worm egg floating method by 1.24 times and the PCR detection rate of dog dung by 1.16 times through paralysis tapeworm, thereby obviously improving the detection sensitivity. In addition, the tapeworm paralytic agent, the quick-release agent and the like are coated by the phagostimulant, so that the dog can not swallow the medicine and the medicine feeding is more convenient.
Description
Technical Field
The invention relates to the technical field of control of taeniasis canis, in particular to a cathartic formula for improving the detection sensitivity of taeniasis canis feces and a preparation method of the cathartic for improving the detection sensitivity of the taeniasis canis feces.
Background
Echinococcus, also known as echinococcus, is a parasite that can cause serious co-morbidity between humans and animals, usually echinococcosis or echinococcosis, in cases where the infected larvae are located in carnivores of the canine family, and larvae (echinococcosis) are located in humans and various herbivorous and other animals.
Echinococcosis is widely distributed in regions, and is continuously diffused along with the development of the animal husbandry in the world, so that echinococcosis becomes an important public health and economic problem in the world. The detection of Echinococcus by canine feces (including PCR technology and microscopic detection) is the internationally accepted "gold standard" for the definitive diagnosis of Echinococcus disease. However, the low frequency of dog defecation affects the efficiency of sample collection, and in addition, the low content of Echinococcus ova/polypide in the conventional feces affects the detection sensitivity and detection rate. In order to increase the total defecation amount of dogs (increase the single defecation amount or increase the defecation times), laxatives are generally used, and the conventional laxatives have peculiar smell, are sensitive to smell and dislike phagocytosis.
Disclosure of Invention
Problem (A)
In conclusion, the problem to be solved by the technical personnel in the field is how to provide a canine cathartic, which can promote the canine animal to actively take cathartic, increase the defecation frequency of the canine animal and improve the detection rate of echinococcus tapeworm eggs/bodies in feces.
(II) technical scheme
The invention provides a purgative formula for improving the detection sensitivity of cestodiasis faeces, and the purgative formula for improving the detection sensitivity of the cestodiasis faeces comprises the following components in parts by weight per Kg of a dog:
0.002g to 0.008g of a taenia paralytic agent;
3g to 6g of an quick-release agent;
3g to 6g of a binder;
and 9.2g to 20.4g of phagostimulant.
Preferably, in the purgative formulation for improving the stool detection sensitivity of the taeniasis canis provided by the invention, the taeniasis paralytic agent comprises homobetuline hydrobromide and/or arecoline hydrobromide.
Preferably, in the purgative formulation for improving the fecal detection sensitivity of the cestodiasis canis provided by the present invention, the fast purgative comprises mannitol and magnesium sulfate; wherein the dosage of the mannitol is 2g to 4g, and the dosage of the magnesium sulfate is 1g to 2 g.
Preferably, in the purgative formulation for improving the fecal detection sensitivity for cestodiasis canis provided by the present invention, the binder comprises gelatin, starch, dextrin, lactose and/or microcrystalline cellulose; wherein the starch is a compressible starch.
Preferably, in the purgative formulation for improving the detection sensitivity of the cestodiasis faeces provided by the invention, the phagostimulant comprises glucose, chicken liver powder, sodium dihydrogen phosphate, yeast extract and animal fat; wherein the dosage of the glucose is 2g to 6g, the dosage of the chicken liver powder is 6g to 10g, the dosage of the sodium dihydrogen phosphate is 0.1g to 0.4g, the dosage of the yeast extract is 0.1g to 2g, and the dosage of the animal fat is 1g to 2 g.
The invention also provides a preparation method of the cathartic for improving the detection sensitivity of the cestodiasis faeces, and in the preparation method of the cathartic for improving the detection sensitivity of the cestodiasis faeces, the components in the cathartic formula for improving the detection sensitivity of the cestodiasis faeces are weighed for later use; then, mixing the tapeworm paralytic agent and the quick-release agent, and preparing a liquid capsule by adopting an adhesive; finally, preparing the phagostimulant into a shell, and putting the liquid capsule into the shell to be pressed into tablets.
Preferably, in the preparation method of the purgative for improving the detection sensitivity of the cestodiasis faeces provided by the invention, each compressed tablet is packaged separately.
The invention also provides a preparation method of the cathartic for improving the detection sensitivity of the cestodiasis faeces, and in the preparation method of the cathartic for improving the detection sensitivity of the cestodiasis faeces, the components in the cathartic formula for improving the detection sensitivity of the cestodiasis faeces are weighed for later use; then, mixing the tapeworm paralytic agent and the quick-release agent, and pressing the mixture into tablets by adopting an adhesive; and finally, preparing the phagostimulant into a shell, and placing the tabletting into the shell to be pressed into tablets.
Preferably, in the preparation method of the purgative for improving the detection sensitivity of the cestodiasis faeces, provided by the invention, the cestodiasis paralytic, the quick-purging agent and the binder are mixed, disintegrated and pressed into the tablet.
Preferably, in the preparation method of the purgative for improving the detection sensitivity of the cestodiasis faeces provided by the invention, each compressed tablet is packaged separately.
(III) advantageous effects
The invention provides a purgative formula for improving the detection sensitivity of cestodiasis faeces, and the purgative formula for improving the detection sensitivity of the cestodiasis faeces comprises the following components in parts by weight per Kg of a dog: 0.002g to 0.008g of a taenia paralytic agent; 3g to 6g of an quick-release agent; 3g to 6g of a binder; and 9.2g to 20.4g of phagostimulant. The invention also provides a preparation method of the cathartic for improving the detection sensitivity of the cestodiasis faeces, which is characterized in that the components in the cathartic formula for improving the detection sensitivity of the cestodiasis faeces are weighed for later use; mixing the taenia paralytic agent and the quick-release agent, and pressing into tablets by adopting an adhesive; preparing the phagostimulant into a shell, and putting the tabletting into the shell to be pressed into tablets. By using the medicament provided by the invention, the average defecation time of the dog can be reduced by 2.75 times, and the sample obtaining efficiency is obviously improved. The agent provided by the invention can improve the detection rate of dog dung and dog dung worm egg floating method by 1.24 times and the PCR detection rate of dog dung by 1.16 times through paralysis tapeworm, thereby obviously improving the detection sensitivity. In addition, the tapeworm paralytic agent, the quick-release agent and the like are coated by the phagostimulant, so that the dog can not swallow the medicine and the medicine feeding is more convenient.
Detailed Description
The following examples further describe embodiments of the present invention in detail. The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
The invention provides a purgative formula for improving the detection sensitivity of cestodiasis faeces, which is prepared according to the usage amount of each Kg of body weight of a dog. In the invention, the purgative formula for improving the detection sensitivity of the cestodiasis faeces comprises a cestode paralytic agent, a quick-purging agent, an adhesive and a phagostimulant. After entering the dog body, the taenia paralytic agent has a paralytic effect on the taenia, so that the taenia falls off from the intestinal wall and is discharged out of the dog body along with excrement. Fast-purgative agents are agents that stimulate the excretion of canines. The adhesive is used for mixing the taenia paralytic agent and the quick-release agent to prepare a primary substance of a tablet or a liquid capsule. The phagostimulant is coated on the outer side of the tablet or the liquid capsule to induce the dog to swallow actively.
In the invention, the content of the taenia paralytic agent is 0.002g to 0.008g, the content of the quick-release agent is 3g to 6g, the content of the adhesive is 3g to 6g, and the content of the phagostimulant is 9.2g to 20.4 g.
The phagostimulant used in the present invention is mainly food that dogs like to eat, and should be unable to react with tapeworm paralytic agents, quick-purging agents and adhesives.
Specifically, in the invention, the lappaconitine hydrobromide and/or the synthetic arecoline hydrobromide are/is used as the tapeworm paralytic agent, wherein the lappaconitine hydrobromide and the synthetic arecoline hydrobromide can be used together or separately.
Specifically, mannitol and magnesium sulfate are simultaneously selected as the quick-purging agent, wherein the dosage of the mannitol is 2g to 4g, and the dosage of the magnesium sulfate is 1g to 2 g.
Specifically, in the present invention, one or a combination of any more of gelatin, starch, dextrin, lactose and microcrystalline cellulose is selected as the binder. Particularly, when starch is selected as a binder for preparing the tablet, the starch is selected from compressible starch. When preparing the liquid capsule, gelatin, lactose and microcrystalline cellulose are selected as the adhesive.
Specifically, in the invention, glucose, chicken liver powder, sodium dihydrogen phosphate, yeast extract and animal fat are selected as the phagostimulant. Wherein the dosage of the glucose is 2g to 6g, the dosage of the chicken liver powder is 6g to 10g, the dosage of the sodium dihydrogen phosphate is 0.1g to 0.4g, the dosage of the yeast extract is 0.1g to 2g, and the dosage of the animal fat is 1g to 2 g.
The content only discloses a purgative formula for improving the detection sensitivity of the cestodiasis faeces, and based on the purgative formula, the invention also provides a preparation method of the purgative for improving the detection sensitivity of the cestodiasis faeces. The components of the present invention may be weighed completely according to the above-mentioned limited mass, or may be weighed in multiples. Then, the taenia paralytic agent and the quick-release agent are mixed and made into liquid capsules by adopting an adhesive. When the liquid capsule is prepared, the material is required to be evenly divided into N parts to prepare the single liquid capsules. Finally, preparing the phagostimulant into a shell, and putting the liquid capsule into the shell to be pressed into tablets. And then, packaging each tablet individually, and boxing and delivering out of the warehouse.
In the above embodiment, the taenia paralytic, the quick-release agent and the adhesive are mixed to prepare the liquid capsule. In this example, a taenia paralytic, a laxative, and a binder were mixed and tableted.
Specifically, the components of the purgative formulation described above are first weighed for use. The components of the present invention may be weighed completely according to the above-mentioned limited mass, or may be weighed in multiples. Then, the taenia paralytic agent and the quick-release agent are mixed and pressed into tablets by adopting an adhesive. When the double weighing is adopted, for example, when the double weighing is carried out according to N times, wherein N is a positive integer larger than or equal to 1, when the tabletting is prepared, the material needs to be evenly divided into N parts to be prepared into single tabletting. And finally, preparing the phagostimulant into a shell, and placing the tabletting into the shell to be pressed into tablets. And then, packaging each tablet individually, and boxing and delivering out of the warehouse.
Furthermore, the invention mixes the tapeworm paralytic, the quick-release agent and the adhesive, adopts a disintegration mode to prepare powder and then presses the powder into the tablet.
The invention relates to a purgative formula or a medicinal composition for improving the detection sensitivity of taeniasis canis, wherein the formula of the quick-purging agent is mannitol and magnesium sulfate; the phagostimulant is glucose, chicken liver powder, sodium dihydrogen phosphate, yeast extract and animal fat, and the adhesive is starch. The preparation method of the medicine comprises mixing the taenia paralytic agent and the quick-release agent by weight to prepare a liquid capsule, or mixing, disintegrating and directly tabletting to prepare a pill core (tablet), preparing the phagostimulant by weight to prepare a shell, placing the liquid capsule or the tablet in the center of the shell, and pressing to obtain the finished product with the required shape. The preparation provided by the invention can obviously improve the sample obtaining efficiency and the detection sensitivity.
As a preferable technical scheme of the invention, the taenia paralytic agent comprises the hydrobromic acid champagne and (or) the synthetic hydrobromic acid arecoline, and the dosage of per kilogram of the weight of the dog is 2-8 mg.
The preferred technical scheme of the invention is that the quick-diarrhea agent comprises mannitol and magnesium sulfate, the dosage of the quick-diarrhea agent per kilogram of body weight of the dog is 2-4g of mannitol and 1-2g of magnesium sulfate, and the optimal ratio of the mannitol to the magnesium sulfate is 2: 1.
as a preferred embodiment of the present invention, the binder is mainly used to fill the weight or volume of the tablet, thereby facilitating tabletting. But are not limited to, starches (e.g., compressible starches), dextrins, lactose, microcrystalline cellulose, and the like.
Mixing above taenia paralytic agent and quick-release agent by weight, and making into liquid capsule with gelatin, cellulose, polysaccharide, etc., or making into pill core (tablet) by mixing, disintegrating and directly tabletting. Then, the phagostimulant is made into a shell according to the weight. And placing the liquid capsule or the tablet in the center of the shell, and pressing into a required shape to obtain the finished product with the filling. Each sandwich finished product is tabletted into 1 small package, the weight of the dog is weighed or estimated when the tablet is used, and the tablet is administrated for 1 small package per kilogram of the weight.
One test example of the present invention is as follows:
for 62 grazing dogs, cestode egg detection was performed by using an egg floating method and a PCR method, and the group A was set without feeding the drug provided by the present invention, and the group B was set using the drug provided by the present invention. And (3) carrying out the A group test, then carrying out the B group test, and respectively recording the average defecation time, the worm egg floating method and the PCR method detection result of each group of dogs.
The results were: by using the medicament provided by the invention, the average defecation time of the dog can be reduced by 2.75 times, and the sample obtaining efficiency is obviously improved. The agent provided by the invention can improve the detection rate of dog dung and dog dung worm egg floating method by 1.24 times and the PCR detection rate of dog dung by 1.16 times through paralysis tapeworm, thereby obviously improving the detection sensitivity.
The embodiments of the present invention have been presented for purposes of illustration and description, and are not intended to be exhaustive or limited to the invention in the form disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art. The embodiment was chosen and described in order to best explain the principles of the invention and the practical application, and to enable others of ordinary skill in the art to understand the invention for various embodiments with various modifications as are suited to the particular use contemplated.
Claims (10)
1. A purgative formula for improving the detection sensitivity of the cestodiasis excrements is characterized in that,
the dosage of the composition is used per Kg of body weight of dogs and comprises the following components:
0.002g to 0.008g of a taenia paralytic agent;
3g to 6g of an quick-release agent;
3g to 6g of a binder;
and 9.2g to 20.4g of phagostimulant.
2. The purgative formulation for improving the sensitivity of fecal detection of cestodiasis in dogs according to claim 1,
the taenia paralytic agent comprises lappaconitine hydrobromide and/or synthetic arecoline hydrobromide.
3. The purgative formulation for improving the sensitivity of fecal detection of cestodiasis in dogs according to claim 1,
the quick-release agent comprises mannitol and magnesium sulfate;
wherein the dosage of the mannitol is 2g to 4g, and the dosage of the magnesium sulfate is 1g to 2 g.
4. The purgative formulation for improving the sensitivity of fecal detection of cestodiasis in dogs according to claim 1,
the binder comprises gelatin, starch, dextrin, lactose and/or microcrystalline cellulose;
wherein the starch is a compressible starch.
5. The purgative formulation for improving the sensitivity of fecal detection of cestodiasis in dogs according to claim 1,
the phagostimulant comprises glucose, chicken liver powder, sodium dihydrogen phosphate, yeast extract and animal fat;
wherein the dosage of the glucose is 2g to 6g, the dosage of the chicken liver powder is 6g to 10g, the dosage of the sodium dihydrogen phosphate is 0.1g to 0.4g, the dosage of the yeast extract is 0.1g to 2g, and the dosage of the animal fat is 1g to 2 g.
6. A preparation method of purgative for improving the detection sensitivity of cestodiasis faeces is characterized in that,
weighing the components of the purgative formulation for improving the fecal detection sensitivity of cestodiasis canis according to any of claims 1 to 5 for use;
mixing taenia paralytic agent and quick-release agent, and making into liquid capsule with adhesive;
preparing the phagostimulant into a shell, putting the liquid capsule into the shell, pressing the liquid capsule into a mold, and preparing the tablet.
7. The method of claim 6 for improving the sensitivity of fecal detection of cestodiasis in dogs,
each of the compressed tablets was individually packaged.
8. A preparation method of purgative for improving the detection sensitivity of cestodiasis faeces is characterized in that,
weighing the components of the purgative formulation for improving the fecal detection sensitivity of cestodiasis canis according to any of claims 1 to 5 for use;
mixing the taenia paralytic agent and the quick-release agent, and pressing into tablets by adopting an adhesive;
preparing the phagostimulant into a shell, and putting the tabletting into the shell to be pressed into tablets.
9. The method of claim 8 for improving the sensitivity of detecting cestodiasis in a dog,
mixing and disintegrating the taenia paralytic agent, the quick-release agent and the adhesive, and pressing into the tablet.
10. The method of claim 8 or 9 for improving the sensitivity of detecting cestodiasis in dogs,
each of the compressed tablets was individually packaged.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110161432.0A CN112755049A (en) | 2021-02-05 | 2021-02-05 | Laxative formula for improving dog cestodiasis excrement detection sensitivity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110161432.0A CN112755049A (en) | 2021-02-05 | 2021-02-05 | Laxative formula for improving dog cestodiasis excrement detection sensitivity and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112755049A true CN112755049A (en) | 2021-05-07 |
Family
ID=75705111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110161432.0A Pending CN112755049A (en) | 2021-02-05 | 2021-02-05 | Laxative formula for improving dog cestodiasis excrement detection sensitivity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112755049A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB840239A (en) * | 1958-01-21 | 1960-07-06 | Boots Pure Drug Co Ltd | New anthelmintic compositions |
| CN1299972A (en) * | 2000-09-08 | 2001-06-20 | 新疆维吾尔自治区地方病防治研究所 | Enzyme linked immunosorbent reagent kit for dog stool antigen detection |
| US20040202738A1 (en) * | 2003-04-08 | 2004-10-14 | Gow Robert T. | Methods and compositions of areca catechu |
| CN103957701A (en) * | 2011-09-12 | 2014-07-30 | 梅里亚有限公司 | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof |
| CN107402298A (en) * | 2016-05-18 | 2017-11-28 | 上海新吉而生物科技有限公司 | A kind of dog excrement echinococcosis antigen quick detection kit and its application method |
| CN107510669A (en) * | 2016-06-16 | 2017-12-26 | 游锡火 | A kind of dog containing phagostimulant, cat dropping pill formulation |
-
2021
- 2021-02-05 CN CN202110161432.0A patent/CN112755049A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB840239A (en) * | 1958-01-21 | 1960-07-06 | Boots Pure Drug Co Ltd | New anthelmintic compositions |
| CN1299972A (en) * | 2000-09-08 | 2001-06-20 | 新疆维吾尔自治区地方病防治研究所 | Enzyme linked immunosorbent reagent kit for dog stool antigen detection |
| US20040202738A1 (en) * | 2003-04-08 | 2004-10-14 | Gow Robert T. | Methods and compositions of areca catechu |
| CN103957701A (en) * | 2011-09-12 | 2014-07-30 | 梅里亚有限公司 | Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof |
| CN107402298A (en) * | 2016-05-18 | 2017-11-28 | 上海新吉而生物科技有限公司 | A kind of dog excrement echinococcosis antigen quick detection kit and its application method |
| CN107510669A (en) * | 2016-06-16 | 2017-12-26 | 游锡火 | A kind of dog containing phagostimulant, cat dropping pill formulation |
Non-Patent Citations (2)
| Title |
|---|
| 赵玉敏，等: "甘南藏族自治州终末宿主犬感染棘球绦虫状况调查", 《中国病原生物学杂志》 * |
| 金德磊: "槟榔碱及其片剂的制备与质量标准的制定", 《中国优秀硕士学位论文全文数据库农业科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1088362C (en) | Method of administering azithromycin | |
| CN101664421B (en) | Traditional Chinese biological preparation for preventing and treating livestock diarrhea and preparation method and feedstuff thereof | |
| CN105395676B (en) | A kind of compound medicament composition for treating animal mycotoxicosis | |
| EP0412125B1 (en) | Pharmaceutical dosage form for the medication of fish | |
| PL185332B1 (en) | Chewing tablets containing flubendazole for man accompanying animals | |
| AU2021323853B2 (en) | Milbemycin oxime and praziquantel flavor tablets and preparation method therefor | |
| Marsboom | Toxicologic studies on mebendazole | |
| CN112755049A (en) | Laxative formula for improving dog cestodiasis excrement detection sensitivity and preparation method thereof | |
| CA2915435A1 (en) | Composition for the treatment of progressive renal diseases | |
| CN101664437A (en) | Traditional Chinese medicine for treating coccidiosis and preparation method and application thereof | |
| CN104523681B (en) | Parasite expelling sustained and controlled-release bolus and preparation method thereof | |
| US20130142894A1 (en) | Health supplement compositions for companion animals and methods of using the same | |
| CN106472533A (en) | A kind of pharmaceutical chemistry of suppression muroid breeding and preparation method thereof | |
| US3281322A (en) | Methods for controlling and treating renal calculi | |
| CN103520267A (en) | Wettable experimental pullorum evapotranspiration and preparation method thereof | |
| US10426840B2 (en) | Oil suspension of metronidazole | |
| CN106924270A (en) | A kind of pharmaceutical composition with weight losing function containing orlistat | |
| CN101628073B (en) | Preparation used for improving sexual function of male and resisting fatigue and preparation method thereof | |
| Beresford et al. | The effectiveness of alginates to reduce the transfer of radiostrontium to the milk of dairy goats | |
| CN116249517B (en) | A kind of Milbemycin oxime praziquantel flavored tablet and preparation method thereof | |
| RU2784057C1 (en) | Antispasmodic, antiulcer and antacid agent | |
| CN103536603A (en) | Wettable sulfamonomethoxine (sodium) powder and preparation method thereof | |
| CN106913552A (en) | A kind of polycarbophil Biocal and preparation method thereof | |
| CN108524523A (en) | The application of the composition of Meloxicam and Thymol, animal antipyretic-antalgic anti-inflammatory agent and preparation method thereof | |
| CN102068536B (en) | A compound traditional Chinese medicine granule and its application in the preparation of drugs for preventing and treating pig digestive tract diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210507 |
|
| RJ01 | Rejection of invention patent application after publication |